BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

3:55 PM
Oct 30, 2018
 |  BC Extra  |  Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America at the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY). Spokesperson Jim Baker said avapritinib would be Blueprint's first commercial launch.

Avapritinib is an inhibitor of stem cell factor receptor tyrosine kinase (c-Kit; KIT; CD117) exon 17 mutations and platelet derived growth factor receptor A (PDGFRA; PDGFR2; CD140A) with the D842V amino acid substitution. In 1H19, Blueprint plans to submit an NDA to FDA for the therapy to treat PDGFRA D842V-driven gastrointestinal stromal tumors.

Clovis Oncology Inc. (NASDAQ:CLVS) said SVP and Chief Commercial Officer Dale Hooks resigned to pursue other opportunities. He joined the cancer company in 2014 and became...

Read the full 650 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >